TEVA PHARMACEUTICALS USA, INC.

Teva Pharmaceuticals received FDA Fast Track designation for emrusolmin (TEV-56286), an investigational small molecule therapy targeting alpha-synuclein protein for Multiple System Atrophy treatment.

Teva Pharmaceuticals received FDA approval and launched the first-ever generic GLP-1 receptor agonist indicated for weight loss in the United States.

Catalyst Pharmaceuticals and SERB S.A. reached a settlement agreement with Lupin that prevents generic competition for FIRDAPSE (amifampridine) until February 25, 2035.

Vanda Pharmaceuticals has requested FDA Commissioner Martin Makary to review the agency's approval of two generic versions of Hetlioz, challenging what it calls an "unacceptable culture of bias" toward generic drugs.

PureTech Health has launched Celea Therapeutics as a new subsidiary focused on respiratory diseases, with deupirfenidone (LYT-100) as its lead Phase 3-ready candidate for idiopathic pulmonary fibrosis.

The FDA has approved Ajovy (fremanezumab-vfrm) for preventive treatment of episodic migraine in children and adolescents aged 6-17 years weighing at least 45 kg, making it the first CGRP antagonist approved for pediatric migraine prevention.

Alvotech, a global biosimilar medicines company, has appointed Linda Jónsdóttir as Chief Financial Officer, bringing 15 years of senior leadership experience from Marel food processing technology company.

Alvotech has acquired Ivers-Lee Group, a Swiss family-owned pharmaceutical packaging company founded in 1947, to expand its assembly and packaging capabilities ahead of three new biosimilar launches in 2025.

Five-year follow-up data from the SEQUOIA study demonstrates zanubrutinib's sustained efficacy in treatment-naive chronic lymphocytic leukemia and small lymphocytic lymphoma patients with del(17p).

Alvotech's Swedish Depository Receipts (SDRs) offering was multiple times oversubscribed, attracting over 3,000 new shareholders and raising approximately SEK 39 million.